This study is looking for new ways to run clinical trials for Alzheimer's disease (AD), dementia, and mild cognitive impairment (MCI). It's testing if a combination of cognitive and functional abilities, called "δ" (delta), can better measure how well treatments work. The study also wants to see if information from caregivers can help identify people who might respond best to treatment. You might be able to join if you are 65-100 years old, have AD or MCI, and can walk on your own. The study will use Donepezil, a standard medication, to see its effects on dementia severity. The main goal is to see how Donepezil affects "δ" over 24 weeks.

Study design

This is a double-blind study, meaning neither you nor the study team will know if you're in a specific group. It plans to include 200 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Your progress will be checked at baseline, and at weeks 4, 12, and 24 after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.